CA2163082A1 - System and method for assessing medical risk - Google Patents
System and method for assessing medical riskInfo
- Publication number
- CA2163082A1 CA2163082A1 CA002163082A CA2163082A CA2163082A1 CA 2163082 A1 CA2163082 A1 CA 2163082A1 CA 002163082 A CA002163082 A CA 002163082A CA 2163082 A CA2163082 A CA 2163082A CA 2163082 A1 CA2163082 A1 CA 2163082A1
- Authority
- CA
- Canada
- Prior art keywords
- data
- database
- test
- standard deviation
- mean
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H15/00—ICT specially adapted for medical reports, e.g. generation or transmission thereof
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Primary Health Care (AREA)
- Data Mining & Analysis (AREA)
- Biomedical Technology (AREA)
- Databases & Information Systems (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Electrotherapy Devices (AREA)
- Eye Examination Apparatus (AREA)
Abstract
A system and method for assessing the medical risk of a given outcome for a patient comprises obtaining test data from a given patient corresponding to at least one test marker for predicting the medical risk of a given outcome and obtaining at least one variable relating to the given patient and transforming the test data with the variable to produce transformed data for each test markers. A database of transformed data from previously assessed patients is provided and mean and standard deviation values are determined from the database in accordance with the actual occurrence of the given outcome for previously assessed patients. The transformed data is compared with the mean and standard deviation values to assess the likelihood of the given outcome for the given patient and the database is updated with the actual occurrence for the given patient, whereby the determined mean and standard deviation will be adjusted.
Description
1~30~2 ~Y~-lL I AND M~;-1~OL~ FOR ASSESSING MEDICAL RISR
RZ~CR--'ROUND OF THE lNV~iN-llON
The present invention relates to a system and method of assessing the medical risk of a given outcome for a given patient, and, in particular to prenatal risk evaluation.
Maternal serum alpha-fetoprotein (MSAFP) screening for the detection of fetal abnormalities and abnormal pregnancies has been used for over twenty years by obstetricians and geneticists. AFP screening is particularly applicable to women who conceive over the age of 3~, a time point at which the incidence of abnormal pregnancies and fetal defects increases dramatically. An elevation in MSAFP is associated with a number of fetal anomalies, including open neural tube defects such as spina bifida and anencephaly, congenital nephrosis, and gastrointestinal tract abnormalities.
In 1984, a low maternal serum AFP level was reported to be predictive of fetal chromosomal anomalies as well, including the risk of Down's Syndrome. Since a low maternal serum AFP value is effective in identifying only 20~ of Down's Syndrome affected cases, additional markers were sought which could add to the predictive value of this test. Maternal serum human chorionic gonadotropin (hCG) and unconjugated estriol (uE3) levels have both been described W094/27490 PCT~S94/04690 2~ Qg2 2 .
as providing additional information, useful for estimating the probability of fetal ~own's Syndrome.
The evidence that hCG measurements provide an additional prognostic marker of Down's Syndrome risk in afflicted pregnancies is considerably stronger than the contribution of unconjugated estriol (uE3). However, many laboratories have incorporated all three tests, AFP, hCG, and uE3, for prenatal screening programs targeted at high risk pregnancy populations.
In the course of attempting to optimize the use of MSAFP testing, a number of variables have been identified which can influence the interpretation of AFP results.
Besides developing normative data matched to the gestational period, since AFP appears in the maternal circulation normally with increasing concentration as pregnancy develops, maternal weight, race and diabetic status have also been shown to be confounding variables which can alter the reference base by which one judges the result to be normal or abnormal. This has necessitated the establishment of median values for MSAFP from a normal, healthy pregnancy population between 14 and 20 weeks of gestation (EGA).
Also, the normal variability of MSAFP at each week of gestation has been evaluated, and found to span a range of 2.5 multiples of the median (MoM). Once the MoM value from the MSAFP is calculated, the influence of maternal weight, race, and diabetic status on the MoM calculation is W094/274901 PCT~S94/0~90 ~ ~B3~8~
determined using correction factors established from the literature. The final adjusted MoM value is interpreted by comparison to the normal database. The clinical interpretation of these markers is dependent on their relationship to each other, as well as the specimen source and EGA.
SUMMARY OF THE lNv~NLlON
The main object of the present invention is to provide an optimal and efficient approach to using the markers to evaluate the combined influence of the numbers (AFP, hCG, and uE3) for a specific EGA and source.
Another object is to provide an interpretative report, integrating all of the test results within the context of the patient's present gestational period, weight, race, and diabetic status, when applicable. Placing the AFP
result on a graph, normalized to MoM range and EGA, further facilitates the interpretation of the results.
The present invention allows for simple entry of data into the system so that all of the information needed to provide appropriate adjustments to the MoM value, including the patient's age, weight, race and diabetic status, is accessible. The system allows printing of an interpretative letter that includes, in tabular form, the raw data for each of the markers tested, the adjusted MoM
value(s), and the probability statistics for Down's Syndrome W094/27490 PCT~S94/0~90 ~63~ 4 ~
based on age alone, and age in combination with all prenatal markers entered. Elevated AFP results are also quantified and presented as an indicator of open neural tube defects.
The system is able to formulate customized statements to accompany those results, depending upon the MoM
calculations. Also included is a graph which shows where the patient's marker value fell in relationship to a normal pregnancy for that particular week of gestation. The use of both numerical and visual data helps to convey the findings and avoids errors.
Another feature of the present invention is the ability to continuously update the reference database and median scores for each week of gestation as more normal pregnancy results are entered therein.
A further feature of the invention is the ability to enter data relating to the actual outcome and to continue to refine and update the normative database used to calculate the median, means and standard deviation values.
The system uses at least one of three prenatal markers: AFP (alpha feto-protein), hCG (human chorionic gonadotrophin), and uE3 (unconjugated estriol). The source for these tests can be patient's (maternal) serum or amniotic fluid. The measured values of these markers are compared to the median for that marker, source and gestational age. Corrections are applied for maternal weight, race and diabetic status.
W094127490 PCT~S94/04690 . ~ 5 ~3~2 A further object of the present invention is to provide validation of the data to achieve a safety critical environment for the system. In accordance with the invention, criteria and re~uirements are set for all of the data that is both entered by the user and calculated by the system so as to prevent errors in data entry, system software and system hardware.
These and other features and advantages of the present invention are achieved in accordance with the present invention by a system and method for assessing the medical risk of a given outcome for a patient with data input means receptive of test data from a given patient corresponding to at least one test marker for predicting the medical risk of a given outcome and at least one variable relating to the given patient, means for transforming the test data with the variable to produce transformed data for each test marker, means storing a database of transformed data from previously assessed patients, means for determining mean and standard deviation values from the database in accordance with the actual occurrence of the given outcome for previously assessed patients, means for comparing the transformed data with the mean and standard deviation values to assess the likelihood of the given outcome for the given patient, and means for updating the database with the actual occurrence for the given patient, W094/27490 PCT~S94/04690 whereby the determined mean and standard deviation will be adjusted.
The system also preferably has means for storing predetermined requirements for risk data comprising the test data, the at least one variable, the transformed data, the determined mean and the determined standard deviation, means for validating the data when received, transformed and determined with regard to the predetermined requirements and means for indicating when the data does not meet the requirements. The validating means preferably includes means for checking the integrity of the database for each comparison with the data therein and each update of the data therein, means for range checking the test markers, the test data and the transformed data for the given patient, means for double copy comparing all data received from and written into the storing means and means for maintaining an archival log of all data changes to the database. When at least two markers are used, the system preferably includes means for correlating the comparisons of the transformed data for the at least two markers. The system and method also include means for storing a plurality of letters, means for selecting a letter based on the transformed data for the given patient and means for printing the selected letter.
The present invention also includes a method of validating data input in a system by a user, comprising the steps of predefining a set of criteria for all data to be W094/27490 PCT~S94/04690 ~ 7 ~ ~3~82 input, storing the set of criteria, presenting the criteria to a user when data is input, comparing the inputted data to the stored criteria, and indicating to the user when the data does not adhere to the stored criteria. Preferably, a set of criteria for data to be calculated is predefined, the calculated data is compared to the stored criteria and an indication is made to the user when the calculated data does not adhere to the criteria. The user is preferably permitted to modify the criteria in response to an indication of non-adherence.
In another embodiment of the invention, a system for validating data input by a user, comprises means storing a predefined set of criteria for all data to be input, means for presenting the criteria to a user when data is input, means for comparing the inputted data to the stored criteria, and means for indicating to the user when the data does not adhere to the stored criteria. The system preferably comprises means for storing a set predefined set of criteria for data to be calculated, means for comparing calculated data to the stored criteria and means for indicating to the user when the calculated data does not adhere to the criteria. In a preferred embodiment, the system further comprises means for permitting the user to modify the criteria in response to an indication of non-adherence.
W094/27490 PCT~S94/04690 ~ ~ These and other features and objects of the present invention will be apparent from the following detailed description of the invention taken with the attached drawings wherein:
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is a block diagram of the system according to the present invention; and Fig. 2 is a flow chart of the method according to the present invention.
DET~TT-~n DESCRIPTION OF THE lNv~NllON
Referring to Fig. 1, the system according to the present invention includes a processor 10 capable of writing data into a memory 16 and reading data from memory 16 as demanded. The processor 10 is also connected to an input/output circuit 12 which accepts data from a data input device including a keyboard, a mouse and/or a floppy disk drive and which outputs data from the processor to a display 11 which includes a monitor and a printer 14 which is preferably a dot matrix, laser or ink jet printer.
In accordance with the invention, elements 10-13 and 16 can be provided by an Apple Macintosh Plus or later computer having two megabytes of RAM, a hard drive including at least 20 megabytes of memory, an operating system comprising system 6.0 or greater and including system 7.
W094/27490 PCT~S94/0~90 9 ~ 2 The printer can be any printer of the above-mentioned type which is capable of printing both text and graphics.
A~other part of the system is validation circuitry 15 which interacts with the processor 10 to provide a safety critical environment for the system. As will be discussed hereinafter, the system and the user set up requirements and criteria for all of the data that is input by the user through data input 13, the data stored in memory 16 as part of the database and the data which is calculated in processor 10 in order to carry out the method of the present invention. Circuitry for effecting the validation circuit 15 is disclosed by way of example in copending U.S.
application serial number 07/964,742 filed October 22, 1992 and U.S. application serial number 07/983,489 filed November 30, 1992, the disclosures of which are incorporated herein by reference.
The data stored in memory 16 comprises the database including patient information, the prenatal test results and letters to be used depending upon the test results as will be described hereinafter.
The processor 10 evaluates the marker values input through data input 13, based on the median score for the test, given the test source and the status of the pregnancy.
These medians use both historical data and those calculated from the test results stored in the database. The W094/27490 PCT~S94/04690 ~,~,G308~ 10 ~
historical medians are included as default values which aid in the validation of data as will be described hereinafter.
Because of the importance of the tests and the ability for errors to either prevent the indication of a risk or to indicate a risk when there is none, a safety critical environment is provided for the system.
Fig. 2 shows the flow chart for the operation of the system of Fig. 1.
Upon the initial set up of the system, a predefined set of criteria and requirements are loaded into memory in step 99. These criteria and requirements include expected values or range of values for all inputted data and calculated data, for example, a measured low and measured high value is input into memory 16 for each marker used.
These represent the expected lowest and highest measurements for that marker and any attempt to enter a value for that marker which is out of the range of these two parameters will result in a warning message being displayed on display 11 .
The system also stores a normal MoM low and normal MoM high value for each marker. These values are used to measure the calculated MoM values for each marker to determine whether an error has occurred in the computation of the MoM values due to either a software or hardware failure. When the calculated MoM value is outside this range, the user is warned of a possible error on display 11.
W094/27490 PCT~S94/04690 2~ag2 While the flow chart shows the inputting of test marker data in step 100, prior to the input of variables in step 101, it is understood that these steps can be reversed.
The data relating to the test marker is input and checked against the range data stored in memory 16 by validation circuit 15. If the input test marker data is outside the expected range for that marker, the display 11 will indicate the failure to meet the requirements in step 100 so that the user must either change the input data or indicate to the system that this unusual data is acceptable, thereby temporarily changing the criteria or requirements of the system.
The same is true for the inputting of variables such as race, weight, age and diabetic status in step 101.
If the data is outside the range of valid data stored in memory 16 and checked by validation circuit 15 in step 201, display 11 will indicate the failure to meet requirements in step 301 and ask the user to reevaluate the data input into the system.
Upon accepting the test marker data and input variables, the system then transforms the test data in step 102 so it can be used with the database in memory 16.
Studies have implicated various maternal variables as effecting the interpretation of AFP results. Black and Asian maternal serum AFP levels are approximately 10~ higher than caucasian levels at the same EGA. Also the levels of := ~
W094/27490 PCT~S94/04690 ~ 12 women with IDDM (Insulin Dependent Diabetes Melitis) is about 40~ higher than those of non-diabetic control patients. It has also been found that maternal weight effects the interpretation of serum AFP levels and it is therefore desirable to alter the MoM based on the current maternal weight.
Thus in the transforming step 102, the test results are adjusted for diabetes and race, the multiple of median is calculated therefrom and the multiple of median is adjusted for the weight of the mother.
Median scores are used to derive the multiple of median for each individual by taking the ratio between the test result and a median value. Medians are classified by gestational age of the fetus (EGA), the prenatal marker and the source of the test. The median can either be preset by the user for each of the markers or it can be calculated from the values in the database. In any event, the normal MoM low and high fields for each marker which are stored in memory 16 are used by the validation circuit to validate the median used in each calculation in step 202 in order to determine whether and error has occurred in either system software of hardware. If the user sets a median value which is outside the normal range, or if the system calculates a median value which is outside a normal range, the system will indicate the failure to meet the requirements of the system in step 302 and require the user to reprocess the W094/27490 PCT~S94/0~90 21 ~3~8~
information or indicate that the system should use this data despite its possible error.
After the multiple of median data is calculated for each marker for the given patient, the processor 16 determines the mean and standard deviation of the values stored in the database for all previously assessed patients for each of the markers. These calculated mean and standard deviation values are compared to predetermined outside range values in step 203 by validation circuitry 15 to determine if these calculated values meet the requirements of the system. If they do not, the system indicates the failure to meet requirements in step 303 on display 11 so that the user is informed of the possibility of either a software of hardware failure or that the database itself has become corrupted.
If the mean and standard deviation values computed by the system are valid, the processor 10 compares the transformed test data from step 102 with the mean and standard deviation values for each marker to determine the risk factors for each marker. The system then correlates the risk factors for all of the test markers in step 105 and determines a computed risk for Down's Syndrome and neural tube defects.
A large body of evidence has been accumulated, associating maternal serum (and to a lesser extent, amniotic fluid) AFP levels with some fetal anomalies. A high serum W094/27490 PCT~S94/0~90 ~3Q~ 14 AFP level, above the cited normal limit of 2.5 times the median for that EGA (2.5 MoM), is associated with an increased risk of open neural tube defects (NTD), presumably because the AFP has leaked through the ND into the amniotic fluid, and eventually, into the maternal blood stream.
Conversely, a low serum AFP level, below 50~ of the median score for that EGA (0.5 MoM), has been associated with fetal Down's Syndrome and, less strongly, to other chromosomal abnormalities, including some of the other trisomies.
Recent work has focused on refining the predictions using AFP, and also evaluating whether hCG or uE3 would make the predictions more sensitive and accurate.
The best method of predicting the risk of fetal Down's Syndrome may well include serum AFP, hCG, and uE3, with a reported detection rate of 60-77~ or greater. The predictive ability for all three markers for other chromosomal anomalies is not as well defined, nor is the applicability of the tests to non-singleton pregnancies.
The most successful prediction of fetal Down's Syndrome, implements a trivariate Gaussian probability distribution to allow for the influence of all three serum tests (AFP, hCG, uE3) on the well described risk predicted by maternal age alone.
As noted hereinbefore, memory 16 also includes a database of letters regarding the results of the prenatal screening tests. A plurality of letters are present, with W094/27490 PCT~S94/04690 ~ ~G3Q~2 each having a prenatal marker range associated with the entered text. One marker is used as the criterion for choosing wh~ch letter to send and the specific value of that . ~
marker obtained from the transformed test data in step 102 is used to select the particular type of letter generated by the system. In each case, no matter which letter is selected by the system, each letter includes a listing of all of the input test marker data, all of the input variables, the calculated mean and standard deviation values, the median value used.
The letter also includes graphical data showing the graphs for each of the markers and where the data for each marker for the given patient falls on that graph.
Another important aspect of the present invention is the incorporation of follow-up data in step 107. After the outcome of the pregnancy is known, information on pregnancy outcome is input into the system to test the accuracy of the predictions and to refine the median and mean and standard deviation values which are determined by the system.
Another feature of the data validation circuitry 15 used by the present invention is the maintaining of an activity and transaction log for the system. Aside from the data kept in the database of memory 16, validation circuit 15 maintains a listing of all data input into the system W094/27490 PCT~S94/04690 ~ 16 each day including information relating to the specific user who input data.
The validation circuitry 15 also provides a quick check on the system database. It scans all of the files and important file relationships in the database in memory 16 to make sure that the data is intact. Specifically, the circuitry checks the database to see if the data meets the requirements and criteria for the data for each test marker and inputted variable. Validating includes checking the integrity of the database for each comparison with the data therein and each update of the data therein, range checking the test markers, the test data and the transformed data for the given patient, double copy comparing all data received from the database and written therein and maintaining an archival log of all data changes to the database.
The processor 10 also has the ability to permit the exchange of data between one system and another through the I/O 12. The data exchange is implemented by a merge and extract function where data can be extracted from one database and placed on a storage median such as a floppy disk and input via data input 13 to the system. The receiving database then merges the extracted data from the storage median into memory 16.
Data that can be merged and extracted includes patient data and median data. Patient data is extracted by selecting individual patients in the existing database and W094l27490 PCT~S94/0~90 ~ 17 ~3~2 copying their data to an extraction file. Median data differs from the patient data in that only contains enough information~to calculate a set of medians.
It will be appreciated that the instant specification and claims as set forth by way of example and illustration and not limitation and that various modifications and changes may be made without departing from the spirit and scope of the present invention.
RZ~CR--'ROUND OF THE lNV~iN-llON
The present invention relates to a system and method of assessing the medical risk of a given outcome for a given patient, and, in particular to prenatal risk evaluation.
Maternal serum alpha-fetoprotein (MSAFP) screening for the detection of fetal abnormalities and abnormal pregnancies has been used for over twenty years by obstetricians and geneticists. AFP screening is particularly applicable to women who conceive over the age of 3~, a time point at which the incidence of abnormal pregnancies and fetal defects increases dramatically. An elevation in MSAFP is associated with a number of fetal anomalies, including open neural tube defects such as spina bifida and anencephaly, congenital nephrosis, and gastrointestinal tract abnormalities.
In 1984, a low maternal serum AFP level was reported to be predictive of fetal chromosomal anomalies as well, including the risk of Down's Syndrome. Since a low maternal serum AFP value is effective in identifying only 20~ of Down's Syndrome affected cases, additional markers were sought which could add to the predictive value of this test. Maternal serum human chorionic gonadotropin (hCG) and unconjugated estriol (uE3) levels have both been described W094/27490 PCT~S94/04690 2~ Qg2 2 .
as providing additional information, useful for estimating the probability of fetal ~own's Syndrome.
The evidence that hCG measurements provide an additional prognostic marker of Down's Syndrome risk in afflicted pregnancies is considerably stronger than the contribution of unconjugated estriol (uE3). However, many laboratories have incorporated all three tests, AFP, hCG, and uE3, for prenatal screening programs targeted at high risk pregnancy populations.
In the course of attempting to optimize the use of MSAFP testing, a number of variables have been identified which can influence the interpretation of AFP results.
Besides developing normative data matched to the gestational period, since AFP appears in the maternal circulation normally with increasing concentration as pregnancy develops, maternal weight, race and diabetic status have also been shown to be confounding variables which can alter the reference base by which one judges the result to be normal or abnormal. This has necessitated the establishment of median values for MSAFP from a normal, healthy pregnancy population between 14 and 20 weeks of gestation (EGA).
Also, the normal variability of MSAFP at each week of gestation has been evaluated, and found to span a range of 2.5 multiples of the median (MoM). Once the MoM value from the MSAFP is calculated, the influence of maternal weight, race, and diabetic status on the MoM calculation is W094/274901 PCT~S94/0~90 ~ ~B3~8~
determined using correction factors established from the literature. The final adjusted MoM value is interpreted by comparison to the normal database. The clinical interpretation of these markers is dependent on their relationship to each other, as well as the specimen source and EGA.
SUMMARY OF THE lNv~NLlON
The main object of the present invention is to provide an optimal and efficient approach to using the markers to evaluate the combined influence of the numbers (AFP, hCG, and uE3) for a specific EGA and source.
Another object is to provide an interpretative report, integrating all of the test results within the context of the patient's present gestational period, weight, race, and diabetic status, when applicable. Placing the AFP
result on a graph, normalized to MoM range and EGA, further facilitates the interpretation of the results.
The present invention allows for simple entry of data into the system so that all of the information needed to provide appropriate adjustments to the MoM value, including the patient's age, weight, race and diabetic status, is accessible. The system allows printing of an interpretative letter that includes, in tabular form, the raw data for each of the markers tested, the adjusted MoM
value(s), and the probability statistics for Down's Syndrome W094/27490 PCT~S94/0~90 ~63~ 4 ~
based on age alone, and age in combination with all prenatal markers entered. Elevated AFP results are also quantified and presented as an indicator of open neural tube defects.
The system is able to formulate customized statements to accompany those results, depending upon the MoM
calculations. Also included is a graph which shows where the patient's marker value fell in relationship to a normal pregnancy for that particular week of gestation. The use of both numerical and visual data helps to convey the findings and avoids errors.
Another feature of the present invention is the ability to continuously update the reference database and median scores for each week of gestation as more normal pregnancy results are entered therein.
A further feature of the invention is the ability to enter data relating to the actual outcome and to continue to refine and update the normative database used to calculate the median, means and standard deviation values.
The system uses at least one of three prenatal markers: AFP (alpha feto-protein), hCG (human chorionic gonadotrophin), and uE3 (unconjugated estriol). The source for these tests can be patient's (maternal) serum or amniotic fluid. The measured values of these markers are compared to the median for that marker, source and gestational age. Corrections are applied for maternal weight, race and diabetic status.
W094127490 PCT~S94/04690 . ~ 5 ~3~2 A further object of the present invention is to provide validation of the data to achieve a safety critical environment for the system. In accordance with the invention, criteria and re~uirements are set for all of the data that is both entered by the user and calculated by the system so as to prevent errors in data entry, system software and system hardware.
These and other features and advantages of the present invention are achieved in accordance with the present invention by a system and method for assessing the medical risk of a given outcome for a patient with data input means receptive of test data from a given patient corresponding to at least one test marker for predicting the medical risk of a given outcome and at least one variable relating to the given patient, means for transforming the test data with the variable to produce transformed data for each test marker, means storing a database of transformed data from previously assessed patients, means for determining mean and standard deviation values from the database in accordance with the actual occurrence of the given outcome for previously assessed patients, means for comparing the transformed data with the mean and standard deviation values to assess the likelihood of the given outcome for the given patient, and means for updating the database with the actual occurrence for the given patient, W094/27490 PCT~S94/04690 whereby the determined mean and standard deviation will be adjusted.
The system also preferably has means for storing predetermined requirements for risk data comprising the test data, the at least one variable, the transformed data, the determined mean and the determined standard deviation, means for validating the data when received, transformed and determined with regard to the predetermined requirements and means for indicating when the data does not meet the requirements. The validating means preferably includes means for checking the integrity of the database for each comparison with the data therein and each update of the data therein, means for range checking the test markers, the test data and the transformed data for the given patient, means for double copy comparing all data received from and written into the storing means and means for maintaining an archival log of all data changes to the database. When at least two markers are used, the system preferably includes means for correlating the comparisons of the transformed data for the at least two markers. The system and method also include means for storing a plurality of letters, means for selecting a letter based on the transformed data for the given patient and means for printing the selected letter.
The present invention also includes a method of validating data input in a system by a user, comprising the steps of predefining a set of criteria for all data to be W094/27490 PCT~S94/04690 ~ 7 ~ ~3~82 input, storing the set of criteria, presenting the criteria to a user when data is input, comparing the inputted data to the stored criteria, and indicating to the user when the data does not adhere to the stored criteria. Preferably, a set of criteria for data to be calculated is predefined, the calculated data is compared to the stored criteria and an indication is made to the user when the calculated data does not adhere to the criteria. The user is preferably permitted to modify the criteria in response to an indication of non-adherence.
In another embodiment of the invention, a system for validating data input by a user, comprises means storing a predefined set of criteria for all data to be input, means for presenting the criteria to a user when data is input, means for comparing the inputted data to the stored criteria, and means for indicating to the user when the data does not adhere to the stored criteria. The system preferably comprises means for storing a set predefined set of criteria for data to be calculated, means for comparing calculated data to the stored criteria and means for indicating to the user when the calculated data does not adhere to the criteria. In a preferred embodiment, the system further comprises means for permitting the user to modify the criteria in response to an indication of non-adherence.
W094/27490 PCT~S94/04690 ~ ~ These and other features and objects of the present invention will be apparent from the following detailed description of the invention taken with the attached drawings wherein:
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is a block diagram of the system according to the present invention; and Fig. 2 is a flow chart of the method according to the present invention.
DET~TT-~n DESCRIPTION OF THE lNv~NllON
Referring to Fig. 1, the system according to the present invention includes a processor 10 capable of writing data into a memory 16 and reading data from memory 16 as demanded. The processor 10 is also connected to an input/output circuit 12 which accepts data from a data input device including a keyboard, a mouse and/or a floppy disk drive and which outputs data from the processor to a display 11 which includes a monitor and a printer 14 which is preferably a dot matrix, laser or ink jet printer.
In accordance with the invention, elements 10-13 and 16 can be provided by an Apple Macintosh Plus or later computer having two megabytes of RAM, a hard drive including at least 20 megabytes of memory, an operating system comprising system 6.0 or greater and including system 7.
W094/27490 PCT~S94/0~90 9 ~ 2 The printer can be any printer of the above-mentioned type which is capable of printing both text and graphics.
A~other part of the system is validation circuitry 15 which interacts with the processor 10 to provide a safety critical environment for the system. As will be discussed hereinafter, the system and the user set up requirements and criteria for all of the data that is input by the user through data input 13, the data stored in memory 16 as part of the database and the data which is calculated in processor 10 in order to carry out the method of the present invention. Circuitry for effecting the validation circuit 15 is disclosed by way of example in copending U.S.
application serial number 07/964,742 filed October 22, 1992 and U.S. application serial number 07/983,489 filed November 30, 1992, the disclosures of which are incorporated herein by reference.
The data stored in memory 16 comprises the database including patient information, the prenatal test results and letters to be used depending upon the test results as will be described hereinafter.
The processor 10 evaluates the marker values input through data input 13, based on the median score for the test, given the test source and the status of the pregnancy.
These medians use both historical data and those calculated from the test results stored in the database. The W094/27490 PCT~S94/04690 ~,~,G308~ 10 ~
historical medians are included as default values which aid in the validation of data as will be described hereinafter.
Because of the importance of the tests and the ability for errors to either prevent the indication of a risk or to indicate a risk when there is none, a safety critical environment is provided for the system.
Fig. 2 shows the flow chart for the operation of the system of Fig. 1.
Upon the initial set up of the system, a predefined set of criteria and requirements are loaded into memory in step 99. These criteria and requirements include expected values or range of values for all inputted data and calculated data, for example, a measured low and measured high value is input into memory 16 for each marker used.
These represent the expected lowest and highest measurements for that marker and any attempt to enter a value for that marker which is out of the range of these two parameters will result in a warning message being displayed on display 11 .
The system also stores a normal MoM low and normal MoM high value for each marker. These values are used to measure the calculated MoM values for each marker to determine whether an error has occurred in the computation of the MoM values due to either a software or hardware failure. When the calculated MoM value is outside this range, the user is warned of a possible error on display 11.
W094/27490 PCT~S94/04690 2~ag2 While the flow chart shows the inputting of test marker data in step 100, prior to the input of variables in step 101, it is understood that these steps can be reversed.
The data relating to the test marker is input and checked against the range data stored in memory 16 by validation circuit 15. If the input test marker data is outside the expected range for that marker, the display 11 will indicate the failure to meet the requirements in step 100 so that the user must either change the input data or indicate to the system that this unusual data is acceptable, thereby temporarily changing the criteria or requirements of the system.
The same is true for the inputting of variables such as race, weight, age and diabetic status in step 101.
If the data is outside the range of valid data stored in memory 16 and checked by validation circuit 15 in step 201, display 11 will indicate the failure to meet requirements in step 301 and ask the user to reevaluate the data input into the system.
Upon accepting the test marker data and input variables, the system then transforms the test data in step 102 so it can be used with the database in memory 16.
Studies have implicated various maternal variables as effecting the interpretation of AFP results. Black and Asian maternal serum AFP levels are approximately 10~ higher than caucasian levels at the same EGA. Also the levels of := ~
W094/27490 PCT~S94/04690 ~ 12 women with IDDM (Insulin Dependent Diabetes Melitis) is about 40~ higher than those of non-diabetic control patients. It has also been found that maternal weight effects the interpretation of serum AFP levels and it is therefore desirable to alter the MoM based on the current maternal weight.
Thus in the transforming step 102, the test results are adjusted for diabetes and race, the multiple of median is calculated therefrom and the multiple of median is adjusted for the weight of the mother.
Median scores are used to derive the multiple of median for each individual by taking the ratio between the test result and a median value. Medians are classified by gestational age of the fetus (EGA), the prenatal marker and the source of the test. The median can either be preset by the user for each of the markers or it can be calculated from the values in the database. In any event, the normal MoM low and high fields for each marker which are stored in memory 16 are used by the validation circuit to validate the median used in each calculation in step 202 in order to determine whether and error has occurred in either system software of hardware. If the user sets a median value which is outside the normal range, or if the system calculates a median value which is outside a normal range, the system will indicate the failure to meet the requirements of the system in step 302 and require the user to reprocess the W094/27490 PCT~S94/0~90 21 ~3~8~
information or indicate that the system should use this data despite its possible error.
After the multiple of median data is calculated for each marker for the given patient, the processor 16 determines the mean and standard deviation of the values stored in the database for all previously assessed patients for each of the markers. These calculated mean and standard deviation values are compared to predetermined outside range values in step 203 by validation circuitry 15 to determine if these calculated values meet the requirements of the system. If they do not, the system indicates the failure to meet requirements in step 303 on display 11 so that the user is informed of the possibility of either a software of hardware failure or that the database itself has become corrupted.
If the mean and standard deviation values computed by the system are valid, the processor 10 compares the transformed test data from step 102 with the mean and standard deviation values for each marker to determine the risk factors for each marker. The system then correlates the risk factors for all of the test markers in step 105 and determines a computed risk for Down's Syndrome and neural tube defects.
A large body of evidence has been accumulated, associating maternal serum (and to a lesser extent, amniotic fluid) AFP levels with some fetal anomalies. A high serum W094/27490 PCT~S94/0~90 ~3Q~ 14 AFP level, above the cited normal limit of 2.5 times the median for that EGA (2.5 MoM), is associated with an increased risk of open neural tube defects (NTD), presumably because the AFP has leaked through the ND into the amniotic fluid, and eventually, into the maternal blood stream.
Conversely, a low serum AFP level, below 50~ of the median score for that EGA (0.5 MoM), has been associated with fetal Down's Syndrome and, less strongly, to other chromosomal abnormalities, including some of the other trisomies.
Recent work has focused on refining the predictions using AFP, and also evaluating whether hCG or uE3 would make the predictions more sensitive and accurate.
The best method of predicting the risk of fetal Down's Syndrome may well include serum AFP, hCG, and uE3, with a reported detection rate of 60-77~ or greater. The predictive ability for all three markers for other chromosomal anomalies is not as well defined, nor is the applicability of the tests to non-singleton pregnancies.
The most successful prediction of fetal Down's Syndrome, implements a trivariate Gaussian probability distribution to allow for the influence of all three serum tests (AFP, hCG, uE3) on the well described risk predicted by maternal age alone.
As noted hereinbefore, memory 16 also includes a database of letters regarding the results of the prenatal screening tests. A plurality of letters are present, with W094/27490 PCT~S94/04690 ~ ~G3Q~2 each having a prenatal marker range associated with the entered text. One marker is used as the criterion for choosing wh~ch letter to send and the specific value of that . ~
marker obtained from the transformed test data in step 102 is used to select the particular type of letter generated by the system. In each case, no matter which letter is selected by the system, each letter includes a listing of all of the input test marker data, all of the input variables, the calculated mean and standard deviation values, the median value used.
The letter also includes graphical data showing the graphs for each of the markers and where the data for each marker for the given patient falls on that graph.
Another important aspect of the present invention is the incorporation of follow-up data in step 107. After the outcome of the pregnancy is known, information on pregnancy outcome is input into the system to test the accuracy of the predictions and to refine the median and mean and standard deviation values which are determined by the system.
Another feature of the data validation circuitry 15 used by the present invention is the maintaining of an activity and transaction log for the system. Aside from the data kept in the database of memory 16, validation circuit 15 maintains a listing of all data input into the system W094/27490 PCT~S94/04690 ~ 16 each day including information relating to the specific user who input data.
The validation circuitry 15 also provides a quick check on the system database. It scans all of the files and important file relationships in the database in memory 16 to make sure that the data is intact. Specifically, the circuitry checks the database to see if the data meets the requirements and criteria for the data for each test marker and inputted variable. Validating includes checking the integrity of the database for each comparison with the data therein and each update of the data therein, range checking the test markers, the test data and the transformed data for the given patient, double copy comparing all data received from the database and written therein and maintaining an archival log of all data changes to the database.
The processor 10 also has the ability to permit the exchange of data between one system and another through the I/O 12. The data exchange is implemented by a merge and extract function where data can be extracted from one database and placed on a storage median such as a floppy disk and input via data input 13 to the system. The receiving database then merges the extracted data from the storage median into memory 16.
Data that can be merged and extracted includes patient data and median data. Patient data is extracted by selecting individual patients in the existing database and W094l27490 PCT~S94/0~90 ~ 17 ~3~2 copying their data to an extraction file. Median data differs from the patient data in that only contains enough information~to calculate a set of medians.
It will be appreciated that the instant specification and claims as set forth by way of example and illustration and not limitation and that various modifications and changes may be made without departing from the spirit and scope of the present invention.
Claims (20)
1. A system for assessing a medical risk of a given outcome for a patient, the system comprising:
data input means receptive of test data from a given patient corresponding to at least one test marker for predicting a medical risk of a given outcome and at least one variable relating to the given patient;
means for transforming the test data with the variable to produce transformed data for each test marker;
means storing a database of transformed data from other medical risk assessment systems for previously assessed patients;
means for determining mean and standard deviation values from the database in accordance with an actual occurrence of the given outcome for previously assessed patients;
means for comparing the transformed data with the mean and standard deviation values to assess a likelihood of the given outcome for the given patient;
and means for locally updating the database of said system with an actual occurrence for the given patient;
wherein the means for determining mean and standard deviation values includes means for locally adjusting determined mean and standard deviation values of said system for the locally updated database, whereby adjusted mean and standard deviation values for said system are adjusted for a particular patient population assessed by said system relative to mean and standard deviation values determined from the database from other medical risk assessment systems.
data input means receptive of test data from a given patient corresponding to at least one test marker for predicting a medical risk of a given outcome and at least one variable relating to the given patient;
means for transforming the test data with the variable to produce transformed data for each test marker;
means storing a database of transformed data from other medical risk assessment systems for previously assessed patients;
means for determining mean and standard deviation values from the database in accordance with an actual occurrence of the given outcome for previously assessed patients;
means for comparing the transformed data with the mean and standard deviation values to assess a likelihood of the given outcome for the given patient;
and means for locally updating the database of said system with an actual occurrence for the given patient;
wherein the means for determining mean and standard deviation values includes means for locally adjusting determined mean and standard deviation values of said system for the locally updated database, whereby adjusted mean and standard deviation values for said system are adjusted for a particular patient population assessed by said system relative to mean and standard deviation values determined from the database from other medical risk assessment systems.
2. The system according to claim 1, further comprising means for storing predetermined requirements for risk data comprising the test data, the at least one variable, the transformed data, determined mean and determined standard deviation, means for validating the data when received, transformed and determined with regard to the predetermined requirements and means for indicating when the data does not meet the requirements.
3. The system according to claim 2, wherein the validating means comprises means for checking the integrity of the database for each comparison with the data therein and each update of the data therein
4. The system according to claim 2, wherein the validating means comprises means for range checking the test markers, the test data and the transformed data for the given patient.
5. The system according to claim 2, wherein the validating means comprises means for double copy comparing all data received from and written into the storing means.
6. The system according to claim 2, wherein the validating means comprises means for maintaining an archival log of all data changes to the database.
7. The system according to claim 1, for use in assessing prenatal risks, wherein test markers include at least one selected from the group consisting of AFP, hCG
and uE3.
and uE3.
8. The system according to claim 7, wherein variables include at least one selected from the group consisting of age, race, weight and diabetic status.
9. The system according to claim 1, wherein at least two markers are used and further comprising means for correlating the comparisons of the transformed data for the at least two markers.
10. The system according to claim 1, further comprising means for storing a plurality of letters, means for selecting a letter based on the transformed data for the given patient and means for printing the selected letter.
11. A method for assessing the medical risk of a given outcome for a patient, comprising the steps of:
obtaining test data from a given patient from a particular patient population corresponding to at least one test marker for predicting a medical risk of a given outcome;
obtaining at least one variable relating to the given patient and transforming the test data with the variable to produce transformed data for each test marker;
providing a database of transformed data from previously assessed patients from other patient populations;
determining mean and standard deviation values from the database is accordance with an actual occurrence of the given outcome for previously assessed patients;
comparing the transformed data with the mean and standard deviation values to assess a likelihood of the given outcome for the given patient; and locally updating the database with an actual occurrence for the given patient and locally adjusting the mean and standard deviation values, whereby adjusted mean and standard deviation values are adjusted for the particular patient population relative to mean and standard deviation values determined from the database from other patient populations.
obtaining test data from a given patient from a particular patient population corresponding to at least one test marker for predicting a medical risk of a given outcome;
obtaining at least one variable relating to the given patient and transforming the test data with the variable to produce transformed data for each test marker;
providing a database of transformed data from previously assessed patients from other patient populations;
determining mean and standard deviation values from the database is accordance with an actual occurrence of the given outcome for previously assessed patients;
comparing the transformed data with the mean and standard deviation values to assess a likelihood of the given outcome for the given patient; and locally updating the database with an actual occurrence for the given patient and locally adjusting the mean and standard deviation values, whereby adjusted mean and standard deviation values are adjusted for the particular patient population relative to mean and standard deviation values determined from the database from other patient populations.
12. The method according to claim 11, further comprising providing predetermined requirements for risk data comprising the test data, the at least one variable, the transformed data, the mean and the standard deviation, validating the data when received, transformed and determined with regard to the predetermined requirements and indicating when the data does not meet the requirements.
13. The method according to the claim 12, wherein the step of validating comprises checking the integrity of the database for each comparison with the data therein and each update of the data therein.
14. The method according to claim 12, wherein the step of validating comprises range checking the test markers, the test data and the transformed data for the given patient.
15. The method according to claim 12, wherein the step of validating comprises double copy comparing all data received from the database and written therein.
16. The method according to claim 12, wherein the step of validating comprises maintaining an archival log of all data changes to the database.
17. The method according to claim 11, for use in assessing prenatal risk, further comprising obtaining test markers including at least one selected from the group consisting of AFP, hCG and uE3.
18. The method according to claim 17, wherein the step of obtaining variables comprising obtaining at least one variable selected from the group consisting of age, race, weight and diabetic status.
19. The method according to claim 1, wherein at least two markers are used and further comprising correlating the comparisons of the transformed data for the at least two markers.
20. The method according to claim 11, further comprising storing a plurality of letters, selecting a letter based on the transformed data for the given patient and printing the selected letter.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US067,305 | 1987-06-29 | ||
| US08/067,305 US5594637A (en) | 1993-05-26 | 1993-05-26 | System and method for assessing medical risk |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2163082A1 true CA2163082A1 (en) | 1994-12-08 |
Family
ID=22075106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002163082A Abandoned CA2163082A1 (en) | 1993-05-26 | 1994-04-29 | System and method for assessing medical risk |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US5594637A (en) |
| EP (1) | EP0700542B1 (en) |
| JP (1) | JPH09500290A (en) |
| AT (1) | ATE172561T1 (en) |
| AU (1) | AU7015694A (en) |
| CA (1) | CA2163082A1 (en) |
| DE (1) | DE69414108T2 (en) |
| WO (1) | WO1994027490A2 (en) |
Families Citing this family (191)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8027809B2 (en) | 1992-11-17 | 2011-09-27 | Health Hero Network, Inc. | Home power management system |
| US5951300A (en) * | 1997-03-10 | 1999-09-14 | Health Hero Network | Online system and method for providing composite entertainment and health information |
| US7970620B2 (en) * | 1992-11-17 | 2011-06-28 | Health Hero Network, Inc. | Multi-user remote health monitoring system with biometrics support |
| US7941326B2 (en) * | 2001-03-14 | 2011-05-10 | Health Hero Network, Inc. | Interactive patient communication development system for reporting on patient healthcare management |
| US9215979B2 (en) * | 1992-11-17 | 2015-12-22 | Robert Bosch Healthcare Systems, Inc. | Multi-user remote health monitoring system |
| US5832448A (en) * | 1996-10-16 | 1998-11-03 | Health Hero Network | Multiple patient monitoring system for proactive health management |
| WO2001037174A1 (en) * | 1992-11-17 | 2001-05-25 | Health Hero Network, Inc. | Method and system for improving adherence with a diet program or other medical regimen |
| US8095340B2 (en) | 1992-11-17 | 2012-01-10 | Health Hero Network, Inc. | Home power management system |
| US7624028B1 (en) * | 1992-11-17 | 2009-11-24 | Health Hero Network, Inc. | Remote health monitoring and maintenance system |
| US8626521B2 (en) * | 1997-11-21 | 2014-01-07 | Robert Bosch Healthcare Systems, Inc. | Public health surveillance system |
| US6330426B2 (en) * | 1994-05-23 | 2001-12-11 | Stephen J. Brown | System and method for remote education using a memory card |
| US8078431B2 (en) | 1992-11-17 | 2011-12-13 | Health Hero Network, Inc. | Home power management system |
| US5307263A (en) * | 1992-11-17 | 1994-04-26 | Raya Systems, Inc. | Modular microprocessor-based health monitoring system |
| US5956501A (en) * | 1997-01-10 | 1999-09-21 | Health Hero Network, Inc. | Disease simulation system and method |
| US7613590B2 (en) * | 1992-11-17 | 2009-11-03 | Health Hero Network, Inc. | Modular microprocessor-based power tool system |
| US20040019259A1 (en) * | 1992-11-17 | 2004-01-29 | Brown Stephen J. | Remote monitoring and data management platform |
| US6968375B1 (en) * | 1997-03-28 | 2005-11-22 | Health Hero Network, Inc. | Networked system for interactive communication and remote monitoring of individuals |
| US20070299321A1 (en) * | 1992-11-17 | 2007-12-27 | Brown Stephen J | Method and apparatus for remote health monitoring and providing health related information |
| US20010011224A1 (en) * | 1995-06-07 | 2001-08-02 | Stephen James Brown | Modular microprocessor-based health monitoring system |
| US8078407B1 (en) | 1997-03-28 | 2011-12-13 | Health Hero Network, Inc. | System and method for identifying disease-influencing genes |
| US5692501A (en) * | 1993-09-20 | 1997-12-02 | Minturn; Paul | Scientific wellness personal/clinical/laboratory assessments, profile and health risk managment system with insurability rankings on cross-correlated 10-point optical health/fitness/wellness scales |
| US8015033B2 (en) | 1994-04-26 | 2011-09-06 | Health Hero Network, Inc. | Treatment regimen compliance and efficacy with feedback |
| US7222079B1 (en) | 1994-06-23 | 2007-05-22 | Ingenix, Inc. | Method and system for generating statistically-based medical provider utilization profiles |
| US5557514A (en) | 1994-06-23 | 1996-09-17 | Medicode, Inc. | Method and system for generating statistically-based medical provider utilization profiles |
| US6242463B1 (en) | 1994-10-31 | 2001-06-05 | Opt-E-Scrip, Inc. | Method and kit for treating illnesses |
| US5572671A (en) * | 1995-02-17 | 1996-11-05 | Base Ten Systems, Inc. | Method for operating application software in a safety critical environment |
| US5946659A (en) * | 1995-02-28 | 1999-08-31 | Clinicomp International, Inc. | System and method for notification and access of patient care information being simultaneously entered |
| US6434531B1 (en) * | 1995-02-28 | 2002-08-13 | Clinicomp International, Inc. | Method and system for facilitating patient care plans |
| AU5530996A (en) * | 1995-03-31 | 1996-10-16 | Michael W. Cox | System and method of generating prognosis reports for corona ry health management |
| NZ314144A (en) * | 1996-02-02 | 1999-04-29 | Smithkline Beecham Corp | Computerised identification of at risk patients diagnosed with depression |
| US6678669B2 (en) * | 1996-02-09 | 2004-01-13 | Adeza Biomedical Corporation | Method for selecting medical and biochemical diagnostic tests using neural network-related applications |
| US5976082A (en) * | 1996-06-17 | 1999-11-02 | Smithkline Beecham Corporation | Method for identifying at risk patients diagnosed with congestive heart failure |
| JP3688822B2 (en) * | 1996-09-03 | 2005-08-31 | 株式会社東芝 | Electronic medical record system |
| DE19638738B4 (en) * | 1996-09-10 | 2006-10-05 | Bundesrepublik Deutschland, vertr. d. d. Bundesministerium für Wirtschaft und Technologie, dieses vertr. d. d. Präsidenten der Physikalisch-Technischen Bundesanstalt | Method for obtaining a diagnostic statement from signals and data of medical sensor systems |
| US6032119A (en) | 1997-01-16 | 2000-02-29 | Health Hero Network, Inc. | Personalized display of health information |
| US5937387A (en) * | 1997-04-04 | 1999-08-10 | Real Age, Inc. | System and method for developing and selecting a customized wellness plan |
| DE19718806A1 (en) * | 1997-05-03 | 1998-11-05 | Forschungszentrum Juelich Gmbh | Diagnosis using respiratory sinus arrhythmia |
| US5956689A (en) * | 1997-07-31 | 1999-09-21 | Accordant Health Services, Inc. | Systems, methods and computer program products for using event specificity to identify patients having a specified disease |
| US6587829B1 (en) * | 1997-07-31 | 2003-07-01 | Schering Corporation | Method and apparatus for improving patient compliance with prescriptions |
| US6230142B1 (en) * | 1997-12-24 | 2001-05-08 | Homeopt, Llc | Health care data manipulation and analysis system |
| US6394952B1 (en) * | 1998-02-03 | 2002-05-28 | Adeza Biomedical Corporation | Point of care diagnostic systems |
| US6267722B1 (en) * | 1998-02-03 | 2001-07-31 | Adeza Biomedical Corporation | Point of care diagnostic systems |
| US6334192B1 (en) * | 1998-03-09 | 2001-12-25 | Ronald S. Karpf | Computer system and method for a self administered risk assessment |
| USD432244S (en) * | 1998-04-20 | 2000-10-17 | Adeza Biomedical Corporation | Device for encasing an assay test strip |
| USD434153S (en) * | 1998-04-20 | 2000-11-21 | Adeza Biomedical Corporation | Point of care analyte detector system |
| US6283923B1 (en) * | 1998-05-28 | 2001-09-04 | The Trustees Of Columbia University In The City Of New York | System and method for remotely monitoring asthma severity |
| US6045501A (en) * | 1998-08-28 | 2000-04-04 | Celgene Corporation | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
| US8521546B2 (en) * | 1998-09-25 | 2013-08-27 | Health Hero Network | Dynamic modeling and scoring risk assessment |
| US7115277B2 (en) * | 1999-03-04 | 2006-10-03 | Allergan, Inc. | Method for enabling delivery of an active agent |
| US20080201168A1 (en) * | 1999-05-03 | 2008-08-21 | Brown Stephen J | Treatment regimen compliance and efficacy with feedback |
| EP1198195A1 (en) * | 1999-06-29 | 2002-04-24 | Intercet, Ltd. | Human cancer virtual simulation system |
| ATE438337T1 (en) * | 2000-02-02 | 2009-08-15 | Gen Hospital Corp | METHOD FOR EVALUATION NEW BRAIN TREATMENTS USING A TISSUE RISK MAP |
| US20020038227A1 (en) * | 2000-02-25 | 2002-03-28 | Fey Christopher T. | Method for centralized health data management |
| US6322504B1 (en) | 2000-03-27 | 2001-11-27 | R And T, Llc | Computerized interactive method and system for determining a risk of developing a disease and the consequences of developing the disease |
| US6957218B1 (en) | 2000-04-06 | 2005-10-18 | Medical Central Online | Method and system for creating a website for a healthcare provider |
| US20020052761A1 (en) * | 2000-05-11 | 2002-05-02 | Fey Christopher T. | Method and system for genetic screening data collection, analysis, report generation and access |
| US7739124B1 (en) | 2000-06-02 | 2010-06-15 | Walker Digital, Llc | System, method and apparatus for encouraging the undertaking of a preventative treatment |
| US6847940B1 (en) * | 2000-06-16 | 2005-01-25 | John S. Shelton | System and methods for providing a health care industry trade show via internet |
| US20020038310A1 (en) * | 2000-07-17 | 2002-03-28 | Reitberg Donald P. | Single-patient drug trials used with accumulated database: genomic markers |
| US6315720B1 (en) * | 2000-10-23 | 2001-11-13 | Celgene Corporation | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
| US20070239490A1 (en) * | 2000-11-02 | 2007-10-11 | Sullivan Daniel J | Computerized risk management module for medical diagnosis |
| US20020123906A1 (en) * | 2000-12-29 | 2002-09-05 | Goetzke Gary A. | Chronic pain patient risk stratification system |
| US7319971B2 (en) * | 2001-01-31 | 2008-01-15 | Corprofit Systems Pty Ltd | System for managing risk |
| WO2002088635A1 (en) * | 2001-04-27 | 2002-11-07 | Matsushita Electric Industrial Co., Ltd. | Significant signal extracting method, recording medium, and program |
| US7925612B2 (en) * | 2001-05-02 | 2011-04-12 | Victor Gogolak | Method for graphically depicting drug adverse effect risks |
| US6778994B2 (en) | 2001-05-02 | 2004-08-17 | Victor Gogolak | Pharmacovigilance database |
| US6789091B2 (en) | 2001-05-02 | 2004-09-07 | Victor Gogolak | Method and system for web-based analysis of drug adverse effects |
| US20020183965A1 (en) * | 2001-05-02 | 2002-12-05 | Gogolak Victor V. | Method for analyzing drug adverse effects employing multivariate statistical analysis |
| US7542961B2 (en) * | 2001-05-02 | 2009-06-02 | Victor Gogolak | Method and system for analyzing drug adverse effects |
| US20020192159A1 (en) * | 2001-06-01 | 2002-12-19 | Reitberg Donald P. | Single-patient drug trials used with accumulated database: flowchart |
| US7461006B2 (en) * | 2001-08-29 | 2008-12-02 | Victor Gogolak | Method and system for the analysis and association of patient-specific and population-based genomic data with drug safety adverse event data |
| US20030171657A1 (en) * | 2002-01-22 | 2003-09-11 | Ralph Leonard | Selection of optimal medication methodology (SOOMM) |
| US20030204419A1 (en) * | 2002-04-30 | 2003-10-30 | Wilkes Gordon J. | Automated messaging center system and method for use with a healthcare system |
| US8775196B2 (en) | 2002-01-29 | 2014-07-08 | Baxter International Inc. | System and method for notification and escalation of medical data |
| US10173008B2 (en) | 2002-01-29 | 2019-01-08 | Baxter International Inc. | System and method for communicating with a dialysis machine through a network |
| US20040167804A1 (en) * | 2002-04-30 | 2004-08-26 | Simpson Thomas L.C. | Medical data communication notification and messaging system and method |
| US20030201697A1 (en) * | 2002-04-30 | 2003-10-30 | Richardson William R. | Storage device for health care facility |
| US20050065817A1 (en) * | 2002-04-30 | 2005-03-24 | Mihai Dan M. | Separation of validated information and functions in a healthcare system |
| US20040172301A1 (en) * | 2002-04-30 | 2004-09-02 | Mihai Dan M. | Remote multi-purpose user interface for a healthcare system |
| US20040176667A1 (en) * | 2002-04-30 | 2004-09-09 | Mihai Dan M. | Method and system for medical device connectivity |
| US20040172300A1 (en) * | 2002-04-30 | 2004-09-02 | Mihai Dan M. | Method and system for integrating data flows |
| US8234128B2 (en) | 2002-04-30 | 2012-07-31 | Baxter International, Inc. | System and method for verifying medical device operational parameters |
| USRE48890E1 (en) | 2002-05-17 | 2022-01-11 | Celgene Corporation | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US20030225596A1 (en) * | 2002-05-31 | 2003-12-04 | Richardson Bill R. | Biometric security for access to a storage device for a healthcare facility |
| US20040078231A1 (en) * | 2002-05-31 | 2004-04-22 | Wilkes Gordon J. | System and method for facilitating and administering treatment to a patient, including clinical decision making, order workflow and integration of clinical documentation |
| US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US20040088189A1 (en) * | 2002-11-06 | 2004-05-06 | Veome Edmond A. | System and method for monitoring , reporting, managing and administering the treatment of a blood component |
| US20050060194A1 (en) * | 2003-04-04 | 2005-03-17 | Brown Stephen J. | Method and system for monitoring health of an individual |
| US7399276B1 (en) * | 2003-05-08 | 2008-07-15 | Health Hero Network, Inc. | Remote health monitoring system |
| US8460243B2 (en) * | 2003-06-10 | 2013-06-11 | Abbott Diabetes Care Inc. | Glucose measuring module and insulin pump combination |
| US7722536B2 (en) | 2003-07-15 | 2010-05-25 | Abbott Diabetes Care Inc. | Glucose measuring device integrated into a holster for a personal area network device |
| US7254566B2 (en) * | 2003-12-22 | 2007-08-07 | Merkle Van D | System and method for medical diagnosis |
| US7282031B2 (en) * | 2004-02-17 | 2007-10-16 | Ann Hendrich & Associates | Method and system for assessing fall risk |
| US8340981B1 (en) | 2004-03-02 | 2012-12-25 | Cave Consulting Group, Inc. | Method, system, and computer program product for physician efficiency measurement and patient health risk stratification utilizing variable windows for episode creation |
| US20050228692A1 (en) * | 2004-04-08 | 2005-10-13 | Hodgdon Darren W | Incentive based health care insurance program |
| US20050234742A1 (en) * | 2004-04-08 | 2005-10-20 | Hodgdon Darren W | Incentive based health care insurance program |
| JP2005309506A (en) * | 2004-04-16 | 2005-11-04 | Fuji Photo Film Co Ltd | Medical information management device, method, and program |
| US20050251054A1 (en) * | 2004-05-10 | 2005-11-10 | Medpond, Llc | Method and apparatus for measurement of autonomic nervous system function |
| CA2858901C (en) | 2004-06-04 | 2024-01-16 | Carolyn Anderson | Diabetes care host-client architecture and data management system |
| DE102004043312A1 (en) * | 2004-09-08 | 2006-03-23 | Ipocare Gmbh & Co. Kg | Patient health disturbance e.g. respiratory insufficiency, medical risk measuring and monitoring method for use in hospital, involves determining risk value from values of physiological parameters of patient and time-based changes |
| US20060122873A1 (en) * | 2004-10-01 | 2006-06-08 | Minotto Francis J | Method and system for managing risk |
| US7443303B2 (en) * | 2005-01-10 | 2008-10-28 | Hill-Rom Services, Inc. | System and method for managing workflow |
| US7682308B2 (en) * | 2005-02-16 | 2010-03-23 | Ahi Of Indiana, Inc. | Method and system for assessing fall risk |
| US7643969B2 (en) * | 2005-03-04 | 2010-01-05 | Health Outcomes Sciences, Llc | Methods and apparatus for providing decision support |
| US20060230097A1 (en) * | 2005-04-08 | 2006-10-12 | Caterpillar Inc. | Process model monitoring method and system |
| US20060229854A1 (en) * | 2005-04-08 | 2006-10-12 | Caterpillar Inc. | Computer system architecture for probabilistic modeling |
| US20060229852A1 (en) * | 2005-04-08 | 2006-10-12 | Caterpillar Inc. | Zeta statistic process method and system |
| US8209156B2 (en) * | 2005-04-08 | 2012-06-26 | Caterpillar Inc. | Asymmetric random scatter process for probabilistic modeling system for product design |
| US7877239B2 (en) * | 2005-04-08 | 2011-01-25 | Caterpillar Inc | Symmetric random scatter process for probabilistic modeling system for product design |
| US7565333B2 (en) * | 2005-04-08 | 2009-07-21 | Caterpillar Inc. | Control system and method |
| US8364610B2 (en) | 2005-04-08 | 2013-01-29 | Caterpillar Inc. | Process modeling and optimization method and system |
| US20060229753A1 (en) * | 2005-04-08 | 2006-10-12 | Caterpillar Inc. | Probabilistic modeling system for product design |
| US20060241972A1 (en) * | 2005-04-26 | 2006-10-26 | Lang Robert G | Medical outcomes systems |
| JP2008546117A (en) * | 2005-06-08 | 2008-12-18 | カーディナル ヘルス ３０３ インコーポレイテッド | System and method for dynamic quantification of disease prognosis |
| US20070061144A1 (en) * | 2005-08-30 | 2007-03-15 | Caterpillar Inc. | Batch statistics process model method and system |
| US7487134B2 (en) * | 2005-10-25 | 2009-02-03 | Caterpillar Inc. | Medical risk stratifying method and system |
| US20070118487A1 (en) * | 2005-11-18 | 2007-05-24 | Caterpillar Inc. | Product cost modeling method and system |
| US20070118398A1 (en) * | 2005-11-18 | 2007-05-24 | Flicker Technologies, Llc | System and method for estimating life expectancy and providing customized advice for improving life expectancy |
| US7499842B2 (en) | 2005-11-18 | 2009-03-03 | Caterpillar Inc. | Process model based virtual sensor and method |
| US20070143140A1 (en) * | 2005-12-19 | 2007-06-21 | Ross S M | Collecting patient opinion information associated with a prescription medication |
| US10468139B1 (en) | 2005-12-28 | 2019-11-05 | United Services Automobile Association | Systems and methods of automating consideration of low body mass risk |
| US7945462B1 (en) | 2005-12-28 | 2011-05-17 | United Services Automobile Association (Usaa) | Systems and methods of automating reconsideration of cardiac risk |
| US8019628B1 (en) | 2005-12-28 | 2011-09-13 | United Services Automobile Association | Systems and methods of automating determination of hepatitis risk |
| US8005694B1 (en) | 2005-12-28 | 2011-08-23 | United Services Automobile Association | Systems and methods of automating consideration of low cholesterol risk |
| US8024204B1 (en) | 2005-12-28 | 2011-09-20 | United Services Automobile Association | Systems and methods of automating determination of low body mass risk |
| US7505949B2 (en) * | 2006-01-31 | 2009-03-17 | Caterpillar Inc. | Process model error correction method and system |
| US20070203810A1 (en) * | 2006-02-13 | 2007-08-30 | Caterpillar Inc. | Supply chain modeling method and system |
| US20080051770A1 (en) * | 2006-08-22 | 2008-02-28 | Synergetics, Inc. | Multiple Target Laser Probe |
| US20080140456A1 (en) * | 2006-09-11 | 2008-06-12 | Glick Gregg W | Evaluating susceptibility to a claim occurring infrequently |
| US8478506B2 (en) | 2006-09-29 | 2013-07-02 | Caterpillar Inc. | Virtual sensor based engine control system and method |
| US20080201173A1 (en) * | 2006-12-05 | 2008-08-21 | Toyohiro Takehara | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
| US7483774B2 (en) * | 2006-12-21 | 2009-01-27 | Caterpillar Inc. | Method and system for intelligent maintenance |
| US20080154811A1 (en) * | 2006-12-21 | 2008-06-26 | Caterpillar Inc. | Method and system for verifying virtual sensors |
| US7787969B2 (en) * | 2007-06-15 | 2010-08-31 | Caterpillar Inc | Virtual sensor system and method |
| US8219414B2 (en) * | 2007-07-16 | 2012-07-10 | Computer Task Group, Inc. | Method of appraising a mammal's health |
| US7831416B2 (en) * | 2007-07-17 | 2010-11-09 | Caterpillar Inc | Probabilistic modeling system for product design |
| US20090030723A1 (en) * | 2007-07-27 | 2009-01-29 | Buchanan Philip D | Method of genetic screening and analysis |
| US7788070B2 (en) * | 2007-07-30 | 2010-08-31 | Caterpillar Inc. | Product design optimization method and system |
| US7542879B2 (en) * | 2007-08-31 | 2009-06-02 | Caterpillar Inc. | Virtual sensor based control system and method |
| AU2008310576B2 (en) * | 2007-10-12 | 2014-01-23 | Patientslikeme, Inc. | Personalized management and comparison of medical condition and outcome based on profiles of community of patients |
| US7593804B2 (en) * | 2007-10-31 | 2009-09-22 | Caterpillar Inc. | Fixed-point virtual sensor control system and method |
| US8224468B2 (en) | 2007-11-02 | 2012-07-17 | Caterpillar Inc. | Calibration certificate for virtual sensor network (VSN) |
| US8036764B2 (en) | 2007-11-02 | 2011-10-11 | Caterpillar Inc. | Virtual sensor network (VSN) system and method |
| DE102007057169A1 (en) | 2007-11-26 | 2009-05-28 | Helmut Rauer | Diagnostic machine for web-based sensor- and evaluation system, has personal-computer-based processor, where machine supplies processed data into diagnostic- and management center over secured internet connection |
| AU2009205956B2 (en) | 2008-01-18 | 2015-07-02 | President And Fellows Of Harvard College | Methods of detecting signatures of disease or conditions in bodily fluids |
| WO2009132275A2 (en) * | 2008-04-25 | 2009-10-29 | Celgene Corporation | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
| US20090271021A1 (en) * | 2008-04-28 | 2009-10-29 | Popp Shane M | Execution system for the monitoring and execution of insulin manufacture |
| US20090293457A1 (en) * | 2008-05-30 | 2009-12-03 | Grichnik Anthony J | System and method for controlling NOx reactant supply |
| US8086640B2 (en) * | 2008-05-30 | 2011-12-27 | Caterpillar Inc. | System and method for improving data coverage in modeling systems |
| US8057679B2 (en) | 2008-07-09 | 2011-11-15 | Baxter International Inc. | Dialysis system having trending and alert generation |
| US10089443B2 (en) | 2012-05-15 | 2018-10-02 | Baxter International Inc. | Home medical device systems and methods for therapy prescription and tracking, servicing and inventory |
| US7917333B2 (en) * | 2008-08-20 | 2011-03-29 | Caterpillar Inc. | Virtual sensor network (VSN) based control system and method |
| US8504390B2 (en) * | 2008-10-03 | 2013-08-06 | Physicians Mutual Insurance Company | System and method for providing variable insurance coverage |
| US8554579B2 (en) | 2008-10-13 | 2013-10-08 | Fht, Inc. | Management, reporting and benchmarking of medication preparation |
| JP5501445B2 (en) | 2009-04-30 | 2014-05-21 | ペイシェンツライクミー， インコーポレイテッド | System and method for facilitating data submission within an online community |
| TR201905423T4 (en) | 2009-05-19 | 2019-05-21 | Celgene Corp | Formulations of 4-amino-2- (2,6-dioxopiperidin-3-yl) isindoline-1,3-dione |
| US8315811B1 (en) * | 2009-08-07 | 2012-11-20 | Mark Evans | Method for quantifying the extent of human-introduced variability in medical test data |
| US20110046972A1 (en) * | 2009-08-20 | 2011-02-24 | Andromeda Systems Incorporated | Method and system for health-centered medicine |
| US20110238439A1 (en) * | 2010-03-25 | 2011-09-29 | Rice William H | Method and system for identifying volatility in medical data |
| EP2596116A4 (en) | 2010-07-23 | 2014-03-19 | Harvard College | Methods of detecting autoimmune or immune-related diseases or conditions |
| US20120053073A1 (en) | 2010-07-23 | 2012-03-01 | President And Fellows Of Harvard College | Methods for Detecting Signatures of Disease or Conditions in Bodily Fluids |
| CN103124795A (en) | 2010-07-23 | 2013-05-29 | 哈佛大学校长及研究员协会 | Methods of detecting diseases or conditions using phagocytic cells |
| WO2012012717A1 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting prenatal or pregnancy-related diseases or conditions |
| US10136845B2 (en) | 2011-02-28 | 2018-11-27 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
| US8793004B2 (en) | 2011-06-15 | 2014-07-29 | Caterpillar Inc. | Virtual sensor system and method for generating output parameters |
| WO2013077977A1 (en) | 2011-11-23 | 2013-05-30 | Remedev, Inc. | Remotely-executed medical diagnosis and therapy including emergency automation |
| KR20150048816A (en) | 2012-08-31 | 2015-05-07 | 백스터 코포레이션 잉글우드 | Medication requisition fulfillment system and method |
| KR101974258B1 (en) | 2012-10-26 | 2019-04-30 | 백스터 코포레이션 잉글우드 | Improved image acquisition for medical dose preparation system |
| US9375079B2 (en) | 2012-10-26 | 2016-06-28 | Baxter Corporation Englewood | Work station for medical dose preparation system |
| US8751039B1 (en) | 2013-02-22 | 2014-06-10 | Remedev, Inc. | Remotely-executed medical therapy device |
| US11585814B2 (en) | 2013-03-09 | 2023-02-21 | Immunis.Ai, Inc. | Methods of detecting prostate cancer |
| NZ771629A (en) | 2013-03-09 | 2022-12-23 | Harry Stylli | Methods of detecting cancer |
| US10119978B2 (en) | 2013-03-15 | 2018-11-06 | Wallac Oy | System and method for determining risk of diabetes based on biochemical marker analysis |
| US20150186023A1 (en) * | 2013-12-30 | 2015-07-02 | Welch Allyn, Inc. | Parameter measuring device with manual override selection |
| JP2017525032A (en) | 2014-06-30 | 2017-08-31 | バクスター・コーポレーション・イングルウッドＢａｘｔｅｒ Ｃｏｒｐｏｒａｔｉｏｎ Ｅｎｇｌｅｗｏｏｄ | Managed medical information exchange |
| PL3182996T3 (en) | 2014-08-22 | 2023-04-17 | Celgene Corporation | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies |
| EP3693742B1 (en) | 2014-09-11 | 2022-04-06 | Harry Stylli | Methods of detecting prostate cancer |
| US11107574B2 (en) | 2014-09-30 | 2021-08-31 | Baxter Corporation Englewood | Management of medication preparation with formulary management |
| US11575673B2 (en) | 2014-09-30 | 2023-02-07 | Baxter Corporation Englewood | Central user management in a distributed healthcare information management system |
| WO2016056631A1 (en) * | 2014-10-08 | 2016-04-14 | 味の素株式会社 | Evaluation method, evaluation device, evaluation program, evaluation system, and terminal device |
| WO2016090091A1 (en) | 2014-12-05 | 2016-06-09 | Baxter Corporation Englewood | Dose preparation data analytics |
| SG11201707114XA (en) | 2015-03-03 | 2017-09-28 | Baxter Corp Englewood | Pharmacy workflow management with integrated alerts |
| WO2016207206A1 (en) | 2015-06-25 | 2016-12-29 | Gambro Lundia Ab | Medical device system and method having a distributed database |
| US20170103181A1 (en) * | 2015-10-08 | 2017-04-13 | Barbara Czerska | Healthcare delivery system |
| KR102476516B1 (en) | 2016-12-21 | 2022-12-09 | 감브로 룬디아 아베 | A medical device system that includes an information technology infrastructure with secure cluster domains supporting external domains. |
| US10093647B1 (en) | 2017-05-26 | 2018-10-09 | Celgene Corporation | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof |
| US10093649B1 (en) | 2017-09-22 | 2018-10-09 | Celgene Corporation | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof |
| US10093648B1 (en) | 2017-09-22 | 2018-10-09 | Celgene Corporation | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof |
| US11894139B1 (en) | 2018-12-03 | 2024-02-06 | Patientslikeme Llc | Disease spectrum classification |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5730016A (en) * | 1980-07-31 | 1982-02-18 | Hitachi Ltd | Interface controlling system |
| US4695471A (en) * | 1984-07-30 | 1987-09-22 | Sloan-Kettering Institute For Cancer Research | Breast cyst fluid screening method for cancer risk assessment |
| JPS61133873A (en) * | 1984-12-03 | 1986-06-21 | Mitsubishi Electric Corp | Semiconductor tester |
| US4870576A (en) * | 1986-03-19 | 1989-09-26 | Realpro, Ltd. | Real estate search and location system and method |
| US5191643A (en) * | 1986-04-04 | 1993-03-02 | Alsenz Richard H | Method and apparatus for refrigeration control and display |
| JPH0648442B2 (en) * | 1986-08-14 | 1994-06-22 | 三菱電機株式会社 | Sequence control device |
| US4864492A (en) * | 1986-09-17 | 1989-09-05 | International Business Machines Corporation | System and method for network configuration |
| JPS63271180A (en) * | 1987-04-30 | 1988-11-09 | Fujitsu Ltd | Testing device for integrated circuit |
| GB8722899D0 (en) * | 1987-09-30 | 1987-11-04 | Kirk D L | Fetal monitoring during labour |
| US4957115A (en) * | 1988-03-25 | 1990-09-18 | New England Medical Center Hosp. | Device for determining the probability of death of cardiac patients |
| US5046499A (en) * | 1988-06-13 | 1991-09-10 | Centocor, Inc. | Method for myocardial infarct risk assessment |
| US5178544A (en) * | 1988-11-16 | 1993-01-12 | Vivigen, Inc. | Graphic method for reporting risk to a patient |
| US5316953A (en) * | 1989-01-17 | 1994-05-31 | Macri James N | Screening method for detecting fetal chromosal abnormalities |
| US5252489A (en) * | 1989-01-17 | 1993-10-12 | Macri James N | Down syndrome screening method utilizing dried blood samples |
| US5258907A (en) * | 1989-01-17 | 1993-11-02 | Macri James N | Method and apparatus for detecting down syndrome by non-invasive maternal blood screening |
| US5324667A (en) * | 1989-01-17 | 1994-06-28 | Macri James N | Method for detecting down sydrown by non-invasive maternal blood screening |
| CA2027751C (en) * | 1989-11-30 | 2001-01-23 | Ronald Evan Norden-Paul | Table modifiable edit functions with order-effective edit rules |
| US5231031A (en) * | 1990-08-17 | 1993-07-27 | Fox Chase Cancer Center | Method for assessing risk of diabetes-associated pathologic conditions and efficacy of therapies for such conditions |
| JP2937440B2 (en) * | 1990-08-21 | 1999-08-23 | 株式会社東芝 | Integrated circuit inspection equipment |
| CA2055056C (en) * | 1990-12-10 | 1996-05-14 | Shih-Gong Li | Graphic definition of range in the selection of data from a database field |
| US5255208A (en) * | 1991-08-08 | 1993-10-19 | Aeg Westinghouse Transportation Systems, Inc. | On-line processor based diagnostic system |
| EP0564459B1 (en) * | 1991-10-24 | 1996-05-15 | Hewlett-Packard GmbH | Apparatus and method for evaluating the fetal condition |
| GB9212133D0 (en) * | 1992-06-09 | 1992-07-22 | Polytechnic South West | Medical signal analyzer |
| US5339261A (en) * | 1992-10-22 | 1994-08-16 | Base 10 Systems, Inc. | System for operating application software in a safety critical environment |
-
1993
- 1993-05-26 US US08/067,305 patent/US5594637A/en not_active Expired - Fee Related
-
1994
- 1994-04-29 EP EP94919100A patent/EP0700542B1/en not_active Expired - Lifetime
- 1994-04-29 CA CA002163082A patent/CA2163082A1/en not_active Abandoned
- 1994-04-29 JP JP7500642A patent/JPH09500290A/en active Pending
- 1994-04-29 DE DE69414108T patent/DE69414108T2/en not_active Expired - Fee Related
- 1994-04-29 AT AT94919100T patent/ATE172561T1/en not_active IP Right Cessation
- 1994-04-29 AU AU70156/94A patent/AU7015694A/en not_active Abandoned
- 1994-04-29 WO PCT/US1994/004690 patent/WO1994027490A2/en active IP Right Grant
- 1994-05-09 US US08/239,811 patent/US5492117A/en not_active Expired - Fee Related
-
1997
- 1997-09-11 US US08/927,931 patent/US5796759A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0700542B1 (en) | 1998-10-21 |
| US5594637A (en) | 1997-01-14 |
| US5796759A (en) | 1998-08-18 |
| WO1994027490A3 (en) | 1995-05-18 |
| ATE172561T1 (en) | 1998-11-15 |
| WO1994027490A2 (en) | 1994-12-08 |
| EP0700542A1 (en) | 1996-03-13 |
| JPH09500290A (en) | 1997-01-14 |
| US5492117A (en) | 1996-02-20 |
| AU7015694A (en) | 1994-12-20 |
| DE69414108T2 (en) | 1999-05-06 |
| DE69414108D1 (en) | 1998-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5492117A (en) | System and method for assessing medical risk | |
| Barnhart et al. | Decline of serum human chorionic gonadotropin and spontaneous complete abortion: defining the normal curve | |
| CN107358018B (en) | Early warning method and device for prenatal and postnatal care examination project | |
| US8019734B2 (en) | Statistical determination of operator error | |
| US6193654B1 (en) | Computerized method and system for measuring and determining neonatal severity of illness and mortality risk | |
| CN110504035B (en) | Medical database and system | |
| Fawsitt et al. | At what price? A cost-effectiveness analysis comparing trial of labour after previous caesarean versus elective repeat caesarean delivery | |
| US7415391B2 (en) | Complex event evaluation systems and methods | |
| US20190180379A1 (en) | Life insurance system with fully automated underwriting process for real-time underwriting and risk adjustment, and corresponding method thereof | |
| US7844641B1 (en) | Quality management in a data-processing environment | |
| US20070226175A1 (en) | Automated medical safety monitoring systems and methods | |
| WO1994027490B1 (en) | System and method for assessing medical risk | |
| Woodall et al. | The use of control charts in healthcare | |
| US20210118571A1 (en) | System and method for delivering polygenic-based predictions of complex traits and risks | |
| JP6644281B2 (en) | True / false judgment system | |
| US20200395125A1 (en) | Method and apparatus for monitoring a human or animal subject | |
| EP4160614A1 (en) | System and method for triggering mental healthcare services based on prediction of critical events | |
| Staffa et al. | Statistical evaluation of diagnostic tests: A primer for pediatric surgeons | |
| Appelbaum | Empirical assessment of innovation in the law of civil commitment: A critique | |
| Werbrouck et al. | Cost–utility analysis of lifestyle interventions to prevent type 2 diabetes in women with prior gestational diabetes | |
| Huynh et al. | Healthcare System Capacity and the COVID-19 Pandemic: International Evidence | |
| Jones et al. | Earned Outcomes Correlate with Reliability-Adjusted Surgical Mortality after Abdominal Aortic Aneurysm Repair and Predict Future Performance | |
| CN116665832A (en) | Intelligent quality control method, device, equipment and storage medium based on patient medical record | |
| CN116776072A (en) | AB experiment calculation method and device based on meta-analysis and Bayesian factors | |
| CN117391505A (en) | Obstetrical medical quality evaluation method and device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 20020429 |